Skip to content

Evidence-based evaluation and central response mechanism study of acupuncture-medicine combination in patients with antihistamine-insensitive chronic urticaria

Evidence-based evaluation and central response mechanism study of acupuncture-medicine combination in patients with antihistamine-insensitive chronic urticaria

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000903
Enrollment
Unknown
Registered
2025-05-07
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic urticaria

Interventions

Control group:Sham acupuncture with Ebastine
Treatment group:Acupuncture with Ebastine

Sponsors

Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria for chronic spontaneous urticaria in the EAACI/GA2LEN/EDF/WAO Urticaria Diagnostic Guidelines (2022 edition) and Chinese Urticaria Diagnostic Guidelines (2018 edition); (2) Right-handed; those who are 18 years old = age = 70 years old with = 6 years of education of both sexes; (3) No metallic implants in the body and no contraindication to fMRI scanning; (4) No use of antihistamines within 2 weeks prior to study entry and no use of steroid hormones or immunosuppressive drugs within 1 month; (5) Previously taken antihistamines and insensitive to antihistamines; (6) Those who are not participating in other ongoing clinical studies; (7) Those who have signed the informed consent form and voluntarily participate in this study. Patients who meet the above seven criteria are eligible for inclusion in this study.

Exclusion criteria

Exclusion criteria: (1) People with claustrophobia and other contraindications to nuclear magnetic examination; (2) Those who are unconscious unable to express subjective discomfort symptoms and psychiatric patients; (3) People with progressive malignant tumors or other serious consumptive diseases easily combined with infection and bleeding; (4) People with serious primary diseases such as cardiovascular hepatic renal digestive and hematopoietic systems; (5) Pregnant and lactating women. Note: Patients who meet any 1 of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
Recurrence rate;

Secondary

MeasureTime frame
Self-Rating Anxiety Scale (SAS);Urticaria Control Test (UCT);Pruritus Visual Analogue Scale (VAS);urticaria activity score over 7 days (UAS7);Chronic Urticaria-Quality of Life (CU-Q2oL);Self-Rating Depression Scale (SDS);Pittsburgh sleep quality index (PSQI);

Countries

China

Contacts

Public ContactZou Zihao

Chengdu University of Traditional Chinese Medicine

568737796@qq.com18482134844

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026